This year, biomarker breakthroughs accelerated the future of dementia detection.

{
  "signal_id": "15205817-63f6-43e9-b3e0-8c8d03168c05",
  "signal_type": "linkedin-post-company",
  "signal_subtype": "linkedinPost",
  "detected_at": "2026-01-08T12:32:29.55+00:00",
  "company": {
    "name": "Danaher",
    "domain": "danaher.com"
  },
  "data": {
    "tags": [
      "Research & Development",
      "Healthcare Technology",
      "Analytics & Insights"
    ],
    "post_url": "https://www.linkedin.com/feed/update/urn:li:activity:7407833127240306688/",
    "num_likes": 132,
    "post_text": "This year, biomarker breakthroughs accelerated the future of dementia detection.\n \n#Alzheimers diagnostics are entering a new era of precision. In 2025, Beckman Coulter Diagnostics received FDA Breakthrough Device Designation for a plasma test measuring key biomarkers, enabling earlier, more accurate detection of Alzheimer’s disease.\n \nAlongside this milestone, our Beacon collaboration with Washington University in St. Louis continues to pioneer next-generation plasma biomarkers, sharpening insights into disease progression and empowering patients to act sooner.\n \nThese advancements promise testing that’s less invasive, more affordable and capable of earlier detection - when interventions can make the greatest impact.\n \nScience in motion means advancing precision diagnostics to change the future of dementia care.\n \nSee how we’re accelerating progress in Alzheimer’s diagnostics → https://bit.ly/4pzpHHg",
    "posted_date": "2025-12-19T17:24:08.418Z"
  }
}

curl https://signals.autobound.ai/v1/signals/15205817-63f6-43e9-b3e0-8c8d03168c05 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"danaher.com","limit":20}'